Answers are grounded in this paper and cite their sources.
Background Bronchoscopy is commonly used in the diagnostic work-up of patients with suspected lung cancer, yet clinicians often lack a simple tool to estimate malignancy risk before the procedure in patients already being considered for bronchoscopic evaluation. Most existing prediction models focus on the malignant potential of pulmonary nodules and rely heavily on imaging features, limiting their applicability to the pre-bronchoscopy setting. This study aimed to develop and internally validate a simplified pre-bronchoscopy risk stratification model using routinely available clinical variables. Methods This single-center retrospective cohort study included 336 patients undergoing evaluation for suspected lung cancer. Candidate predictors were restricted to variables available before bronchoscopy and selected based on clinical relevance, routine availability, and data completeness. From 32 candidate predictors, LASSO regression retained 18 variables, which were entered into a multivariable logistic regression model followed by elimination based on statistical and clinical criteria. A simplified model was then constructed and presented as a nomogram. Model performance was assessed in the full cohort, with bootstrap internal validation using 1,000 resamples; the post-LASSO elimination steps were not repeated within bootstrap samples. Results Three independent predictors were identified: age (odds ratio [OR] = 1.045, 95% confidence interval [CI]: 1.017–1.073, P < 0.001), smoking status (OR = 3.216, 95% CI: 1.847–5.598, P < 0.001), and serum carcinoembryonic antigen (CEA) [ln(CEA + 1), per unit increase] (OR = 4.989, 95% CI: 3.095–8.043, P < 0.001). After bootstrap optimism correction, the model demonstrated a corrected C-statistic of 0.837 and a calibration slope of 0.972, with acceptable discrimination and calibration. In biomarker analysis, serum CEA at a cut-off value of 4.57 ng/mL showed high specificity (94%) but moderate sensitivity (52%), whereas bronchoalveolar lavage fluid (BALF) CEA at 22.6 ng/mL showed higher sensitivity (71%) but lower specificity (57%). Mediation analysis indicated that serum CEA partially mediates the association between smoking and lung cancer (indirect effect: 0.09, 95% CI: 0.02–0.15, P = 0.004). Restricted cubic spline analysis showed a linear association between serum CEA and lung cancer risk, with no nonlinearity ( P = 0.514). Conclusions We developed a simplified clinically oriented pre-bronchoscopy risk stratification model based on age, smoking status, and serum CEA levels. The model estimates malignancy probability within a selected bronchoscopy population and does not determine procedural appropriateness or the optimal diagnostic pathway. For patients already being considered for bronchoscopic evaluation because of suspected lung cancer, this model may serve as an adjunctive tool for estimating malignancy risk and informing clinical prioritization. Given the sample size relative to the number of candidate predictors, the model should be regarded as exploratory and supportive rather than determinative. External validation in broader and more diverse populations is required before clinical implementation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: